Objetivo
There is no sensitive and reliable method to monitor the immune response in the cancer patients vaccinated with a protein or with peptides presented by HLA class II molecules. We will therefore analyse in responding patients if we find a difference in terms of number, specificity, or diversity between anti-MAGE-3 CD4+ T cells before and after vaccination.
Ámbito científico
Convocatoria de propuestas
Data not availableRégimen de financiación
RGI - Research grants (individual fellowships)Coordinador
CHRISTIAN DE DUVE INSTITUTE OF CELLULAR PATHOLOGY
Aportación de la UE
Sin datos
Dirección
Avenue Hippocrate 74
1200 BRUXELLES
Bélgica
1200 BRUXELLES
Bélgica
Coste total
Sin datos